Biogen Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax decreased by 17.5% to $90.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 82.7%, from $521.80M to $90.40M. Over 5 years (FY 2020 to FY 2025), Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax shows an upward trend with a 49.0% CAGR.
other_equity_securities_available_for_sale_accumulated_g_37c569| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $260.60M | $279.40M | $311.20M | $351.60M | $237.80M | $342.70M | $410.70M | $284.10M | $579.70M | $563.10M | $598.90M | $497.50M | $429.60M | $489.00M | $521.80M | $511.70M | $123.90M | $109.60M | $90.40M |
| QoQ Change | — | +7.2% | +11.4% | +13.0% | -32.4% | +44.1% | +19.8% | -30.8% | +104.0% | -2.9% | +6.4% | -16.9% | -13.6% | +13.8% | +6.7% | -1.9% | -75.8% | -11.5% | -17.5% |
| YoY Change | — | — | — | — | -8.7% | +22.7% | +32.0% | -19.2% | +143.8% | +64.3% | +45.8% | +75.1% | -25.9% | -13.2% | -12.9% | +2.9% | -71.2% | -77.6% | -82.7% |